Home / Education / LSD

LSD

A molecule at the start of the modern story, told in full. A forthcoming title in the Metanoia Press library.

Published Updated Last reviewed 2 October 2026

Metanoia Press · In preparation · Synthetic

A semi-synthetic compound, covered for a complete picture

Metanoia's focus is the natural psychedelics, but the family cannot be understood without LSD. It was a molecule that helped open the modern era, shaped a culture, was banned, and, in 2026, returned to late-stage clinical trials. Our forthcoming book tells that full arc: the accidental discovery, the science, the fall, and the 2026 return.

This book is being written.

What the Book Will Cover

From a lab bench to the clinic, twice

I

The discovery

Albert Hofmann, ergot, and the accidental first dose, how a Swiss chemistry program produced one of the best-known psychedelics.

II

The pharmacology

Very high potency, a long duration, and its grip on the 5-HT2A receptor, plus why it lasts so long.

III

The rise & the ban

Early psychiatric promise, cultural explosion, and Schedule I, the decades the science went dark.

IV

The 2026 return

Pharmaceutical LSD back in Phase 3 trials, for depression and for anxiety, with positive topline results announced by the sponsor and not yet peer reviewed. These results come from people with a diagnosis and do not describe healthy adults.

The science in brief

LSD was first synthesized by Albert Hofmann in 1938 and its effects discovered in 1943. It is unusually potent and works, like the natural tryptamines, primarily through the 5-HT2A serotonin receptor, with an unusually long grip that helps explain its many-hour duration. After decades in prohibition, its clinical chapter reopened: in 2026 a pharmaceutical LSD program reported positive topline Phase 3 results in major depressive disorder and in generalized anxiety disorder, announced by the sponsor in company press releases. That program received an FDA breakthrough therapy designation for generalized anxiety in March 2024 and a second, for depression, in September 2026.

Why a natural-psychedelics nonprofit covers a synthetic: because a full map needs it. LSD is a reference point for the modern field, and its 2026 results are part of the story of why this moment matters. We cover it fully, while our own research and education stay centered on the natural sources studied as whole systems. See our focus

Reliability: pharmacology and history are well established (strong). The 2026 clinical results are late-stage but await full peer-reviewed publication and independent replication. They come from people with a diagnosis and do not describe healthy adults. Full sources will accompany the finished book.

Read the published book   See the latest field news   See the whole family